A Phase 4 interventional study of enoxaparin in Venous Thrombosis, sponsored by Sanofi. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-02-03.
Sponsored by Sanofi · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies testing enoxaparin in Venous Thrombosis — 3 open to participants now, 3 under way, 1 of them phase 3. Enoxaparin · Venous Thrombosis.
Among the 42 studies testing enoxaparin in Venous Thrombosis, this one is the 13th largest by enrollment, is the only one that started in 2004, is one of 15 in phase 4, and was the 3rd registered.
785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.
Browse Venous Thrombosis studies →3 of the 42 studies testing enoxaparin in Venous Thrombosis are open now, in 2 countries. Recruiting first, the newest first:
Mayo Hospital Lahore · Sites in Pakistan
Ages 18–80
Yale University · Sites in United States
Ages up to 17
Oregon Health and Science University · Sites in United States
Ages 15–100
By country, each count listing its studies:
Enoxaparin: first FDA approval 1993 (LOVENOX (PRESERVATIVE FREE)), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 7 · Phase 4 15
First in 2002; this study’s year is marked. 1 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 251 is above the median of 152 across 477 interventional studies indexed under Venous Thrombosis.
Median enrollment 114 across the 42 interventional studies. Of the 32 that completed or were terminated, 17 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 42 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 8 studies filed under Venous Thrombosis — fewer than ten, so there is no comparison to draw.
1 of the studies testing enoxaparin in Venous Thrombosis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04924322Phase 3Yale UniversityCatheter-Related Early Thromboprophylaxis With Enoxaparin Studies | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 42 studies testing enoxaparin in Venous Thrombosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study objectives :
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
enoxaparin
Drug: enoxaparin
* All patients will be treated with enoxaparin 1.5 mg/kg, once a day, subcutaneously for up to 10 days. * Long-term oral anticoagulation will be started in all patients after 24 hours of initiation of enoxaparin treatment and continued at least for 3 months.
Frequency of bleeding emerged during the study drug administration; Frequency of bleeding emerged during 3 months of monitorization when the patient is on oral anticoagulants.
Time frame: 3 months
The record gives a start of Dec 2004, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enoxaparin